0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
RSS Email Alerts
Please Wait... Processing your request... Please Wait.

Sign in

Purchase Options

• Subscribe to the journal
• Rent this article ?

A free personal account provides

• Free current issues on The JAMA Network Reader
• Free quizzes on The JAMA Network Challenge
• Commenting and personalized alerts
From The JAMA Network
JAMA Oncology
Brief Report  | 
Somatic Mosaic Mutations in PPM1D and TP53 in the Blood of Women With Ovarian Carcinoma
Elizabeth M. Swisher, MD; Maria I. Harrell, PhD; Barbara M. Norquist, MD; et al.
JAMA Oncology
Original Investigation  | 
Association Between BCR-ABL Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia and Cardiovascular Events, Major Molecular Response, and Overall Survival A Systematic Review and Meta-analysis
Jonathan Douxfils, PharmD, PhD; Hélène Haguet, MBS; François Mullier, PharmD, PhD; et al.
JAMA Oncology
Review  | 
Toxic Effects of Sorafenib in Patients With Differentiated Thyroid Carcinoma Compared With Other Cancers
Gary W. Jean, PharmD; Rene M. Mani, PharmD; Aliza Jaffry, PharmD; et al.
JAMA Internal Medicine
Research Letter  | 
Characteristics and Conflicts of Public Speakers at Meetings of the Oncologic Drugs Advisory Committee to the US Food and Drug Administration
Matthew V. Abola, BA; Vinay Prasad, MD, MPH